Psychotropic Medication Monitoring in a Human Services Organization for Children with Autism Spectrum Disorder: Description and Evaluation of Interdisciplinary Team Review

Bird et al. (2022) tested a team review process for cutting psychotropic meds in kids with autism.

Doctors, behavior analysts, nurses, and parents met each month. They shared graphs of problem behavior, side effects, and sleep.

The team looked at five real cases in a children’s residential program. They voted on whether to lower, stay, or stop each drug.

All five children left the meetings with fewer meds or none at all. No child’s behavior got worse.

Parents and staff said they liked the process, but the paper does not give numbers.

Cox et al. (2022) looked back at 29 teens and also saw bigger gains when behavior plans were tweaked than when pills were tweaked. Both studies say: change behavior first, meds second.

Hoyle et al. (2022) warn that most clinics use weak checklists, not hard behavior data, when they judge if a med works. Bird’s team used daily behavior charts—exactly what the review says is missing.

Smith et al. (2010) found that one in three kids with autism already takes psychotropics. Bird shows a way to undo that trend without harm.

You can copy this team huddle in any agency. Bring the BCBA graphs, the nurse’s side-effect notes, and the parent’s sleep log. Vote with data, not guesswork. One meeting per month can safely peel away unnecessary pills and keep behavior steady.